logo
  

Quoin Pharmaceuticals Prices Offering Of Approx. 4.1 Mln Shares At $1.6/Share; Stock Tanks

Quoin Pharmaceuticals, Ltd. (QNRX), Tuesday announced the pricing of offering of around 4.1 million shares, representing same amount of American Depository Shares or ADS, and warrants, at a combined price of $1.6 per share, to raise approximately $6.5 million.

The specialty pharmaceutical company intends to use the proceeds for corporate-related purposes.

The company stated that the warrants, Series D and Series E, would be exercisable immediately following the date of issuance and would expire in two years and five years, respectively, from their issuance.

The offering is expected to close on or about March 7.

Following the announcement, Quoin's stock is currently tumbling 44.48 percent, to $1.57 over the previous close of $2.9 on the Nasdaq.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Editors Pick
The European Commission announced that it has opened formal proceedings against Meta Platforms to assess whether the owner of Facebook and Instagram may have breached the Digital Services Act or DSA in areas linked to the protection of minors. On the Nasdaq Stock Exchange, Meta shares were losing around 1.1 percent. Retail giant Walmart reported Thursday a profit for the first quarter that soared from last year, reflecting higher gross margins and strong growth across all its operating segments. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. While reporting financial results for the first quarter on Thursday, retail giant Walmart, Inc. (WMT) initiated its adjusted earnings and net sales growth guidance for the second quarter, well above analysts' estimates. It also maintained full-year 2025 outlook. For the second quarter, the company...

This week, we bring a mix of medical breakthroughs and setbacks. Lyko's MDMA therapy could become the first FDA-approved psychedelic treatment if all goes well as planned. A tragic loss occurred in Pfizer's Duchenne trial and a new study has raised concerns about ultra-processed foods. Find out why Long Beach declared a public health emergency and how Novavax's actions signal optimism.

View More Videos
Follow RTT